Search research articles
Contact Us
Filters
Showing results (21-30 of 51) with videos related to
Page
of 6
Sort By:
Antimicrobial Agents and Chemotherapy
|
November 22, 2017
<i>In Vitro</i> Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
Meredith A Hackel, Masakatsu Tsuji, Yoshinori Yamano, et al.
Antimicrobial Agents and Chemotherapy
|
November 22, 2021
<i>In Vitro</i> Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019
James A Karlowsky, Meredith A Hackel, Miki Takemura, et al.
Diagnostic Microbiology and Infectious Disease
|
April 29, 2019
Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth
Meredith A Hackel, Masakatsu Tsuji, Yoshinori Yamano, et al.
Antimicrobial Agents and Chemotherapy
|
June 21, 2017
<i>In Vitro</i> Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
Meredith A Hackel, Masakatsu Tsuji, Yoshinori Yamano, et al.
Antimicrobial Agents and Chemotherapy
|
November 14, 2018
Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
Sean M Stainton, Marguerite L Monogue, Masakatsu Tsuji, et al.
International Journal of Antimicrobial Agents
|
November 25, 2018
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015
James A Karlowsky, Meredith A Hackel, Masakatsu Tsuji, et al.
Microbial Drug Resistance (Larchmont, N.Y.)
|
January 25, 2022
Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials
Patrice Nordmann, Ryan K Shields, Yohei Doi, et al.
Antimicrobial Agents and Chemotherapy
|
May 8, 2023
Erratum for Karlowsky et al., "<i>In Vitro</i> Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019"
James A Karlowsky, Meredith A Hackel, Miki Takemura, et al.
The Lancet. Infectious Diseases
|
June 26, 2021
Placing in-vitro heteroresistance in the context of clinical results
Matteo Bassetti, Roger Echols, Andrew Koren, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 17, 2005
Gatifloxacin therapy for children: turn on the light
Roger Echols, Kamal Hamed, Adriano Arguedas, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 51) with videos related to
Sort By:
Page
of 6
Antimicrobial Agents and Chemotherapy
|
November 22, 2017
<i>In Vitro</i> Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
Meredith A Hackel, Masakatsu Tsuji, Yoshinori Yamano, et al.
Antimicrobial Agents and Chemotherapy
|
November 22, 2021
<i>In Vitro</i> Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019
James A Karlowsky, Meredith A Hackel, Miki Takemura, et al.
Diagnostic Microbiology and Infectious Disease
|
April 29, 2019
Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth
Meredith A Hackel, Masakatsu Tsuji, Yoshinori Yamano, et al.
Antimicrobial Agents and Chemotherapy
|
June 21, 2017
<i>In Vitro</i> Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
Meredith A Hackel, Masakatsu Tsuji, Yoshinori Yamano, et al.
Antimicrobial Agents and Chemotherapy
|
November 14, 2018
Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
Sean M Stainton, Marguerite L Monogue, Masakatsu Tsuji, et al.
International Journal of Antimicrobial Agents
|
November 25, 2018
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015
James A Karlowsky, Meredith A Hackel, Masakatsu Tsuji, et al.
Microbial Drug Resistance (Larchmont, N.Y.)
|
January 25, 2022
Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials
Patrice Nordmann, Ryan K Shields, Yohei Doi, et al.
Antimicrobial Agents and Chemotherapy
|
May 8, 2023
Erratum for Karlowsky et al., "<i>In Vitro</i> Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019"
James A Karlowsky, Meredith A Hackel, Miki Takemura, et al.
The Lancet. Infectious Diseases
|
June 26, 2021
Placing in-vitro heteroresistance in the context of clinical results
Matteo Bassetti, Roger Echols, Andrew Koren, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 17, 2005
Gatifloxacin therapy for children: turn on the light
Roger Echols, Kamal Hamed, Adriano Arguedas, et al.
Page
of 6